Biologics denials at external review

• the question matters

  The outcome turns on which question was put to the reviewer: 83.4% on medical necessity (n=349) against 65.1% on experimental/investigational (n=43) — a gap of 18 points inside the same treatment class.

• most-cited standard

  Reviewers named FDA more than any other standard here — 142 decisions, which came out at 85.2%. Citing a standard and the outcome share a cause; this is not the effect of naming it.

• concentrated

  27% of these disputes involved digestive & gi alone (n=107, 89.7% overturned), so the headline figure for biologics is largely that pairing.

• high volume

  With 392 decisions in 2021-2025, this is among the five most-disputed treatment classes in the published record — one of the few where the numbers are stable enough to read year by year.

California requires each published decision to carry “a detailed case summary that includes the specific standards, criteria, and medical and scientific evidence, if any, that led to the case decision” (Health & Safety Code § 1374.33(h)(1)(K)). These are the elements our extraction found in this class, split by how the decision came out.

Read as description, not instruction. These are patterns in what reviewers wrote, not steps to follow, and no combination of them predicts an outcome. Only codes that cleared the validation gate appear — thirteen did not.

• FDA85.2%142
• American Gastroenterological Association—21
• American College of Rheumatology—17
• NCCN—7
• American Academy of Neurology—5
• American College of Cardiology—4
• MCG / Milliman—3
• American Academy of Dermatology—2

A rate here is the outcome of decisions that named the authority, not the effect of naming it. Reviewers cite the standard they applied; the citation and the outcome share a cause.

• Digestive & GI89.7%107
• Skin93.3%89
• Immune disorders73.5%68
• CNS & neuromuscular—29
• Endocrine & metabolic—18
• Cancer—13
• Genitourinary & kidney—13
• Respiratory—11

Browse all condition classes · Pick your own pair

• Crohn's Disease88.5%61
• Other87.2%47
• Ulcerative Colitis91.7%36
• Psoriasis94.3%35
• Dermatitis90.6%32
• Multiple Sclerosis—21
• Arthritis—20
• Autoimmune Disease—19

• Medical Necessity83.4%349
• Experimental/Investigational65.1%43

Medical-necessity review asks whether the care is needed. Experimental/investigational review asks whether it is likely to be more beneficial than standard therapy — a harder statutory test, and the rates show it.